IX Biopharma Ltd represents values of innovation, excellence, and commitment to health care. With a strong corporate philosophy focused on leveraging cutting-edge technologies, IX Biopharma is dedicated to developing innovative pharmaceutical and biotech solutions that improve patients' lives. The company's research and development efforts prioritize breakthrough therapies, ensuring the highest standards of safety and efficacy. By consistently implementing rigorous scientific methodologies and upholding ethical standards, IX Biopharma aims to transform healthcare by addressing unmet medical needs. Through its continuous pursuit of scientific advancements, the company is committed to creating value for both patients and stakeholders.

IX Biopharma Ltd is primarily present in Singapore.

IX Biopharma Ltd has achieved several significant milestones since its establishment. The company has successfully developed innovative pharmaceutical products and brought them to market. IX Biopharma Ltd has received regulatory approvals for its flagship product, Wafermine, which is a unique sublingual wafer for the treatment of pain and other conditions. The company has also entered into strategic partnerships and collaborations with renowned organizations to further enhance its research and development capabilities. Moreover, IX Biopharma Ltd has expanded its global presence by securing international licensing and distribution agreements. These accomplishments demonstrate the company's commitment to advancing healthcare solutions and driving growth in the biopharmaceutical industry.

IX Biopharma Ltd is a prominent pharmaceutical company specializing in the development and commercialization of innovative therapies. Founded in [year], IX Biopharma has a rich history of catering to the global healthcare industry by providing cutting-edge solutions. The company focuses on leveraging its expertise in proprietary drug delivery platforms to enhance drug efficacy and patient compliance. IX Biopharma boasts an impressive portfolio of products and pipeline candidates across various therapeutic areas. With a commitment to pushing boundaries in pharmaceutical innovation, IX Biopharma continues to pave the way for groundbreaking advancements in patient care and treatment options.

The main competitors of IX Biopharma Ltd in the market are other pharmaceutical companies operating in the biopharmaceutical sector. Some notable competitors include larger established companies such as Pfizer, Novartis, and Johnson & Johnson, as well as smaller biotech firms like Moderna and Gilead Sciences. These competitors strive to develop and market innovative drugs and therapies, often targeting similar disease areas or therapeutic indications. The competitive landscape in the biopharmaceutical sector is highly complex and dynamic, with constant advancements in research and development shaping the market dynamics.

IX Biopharma Ltd is primarily active in the pharmaceutical industry.

The business model of IX Biopharma Ltd is focused on the research, development, and commercialization of innovative pharmaceutical products. The company specializes in novel drug delivery technologies and therapeutic formulations. IX Biopharma aims to create value by continuously developing and improving its proprietary drug delivery platforms, such as WaferiX™ and Buccal Adhesive Tablets (BAT), which offer enhanced drug delivery and patient compliance. Through collaborations and partnerships, IX Biopharma strives to bring its advanced pharmaceutical solutions to market, addressing unmet medical needs and improving treatment options for various diseases and conditions.

Коефициентът на цена спрямо печалбата (КЦП) на IX Biopharma е 4,36.

Коефициентът на цена към оборот (KUV) на IX Biopharma е 2,04.

AlleAktien качественият резултат за IX Biopharma е 4/10.

очаквана IX Biopharma оборотът е 11,62 млн. SGD.

очаквана IX Biopharma печалба е 5,43 млн. SGD.

IX Biopharma Ltd is a Singapore-based company that specializes in the development and marketing of innovative therapies for neuropsychiatric disorders. The company offers a wide range of products and services based on the latest scientific knowledge. The business model of IX Biopharma is based on three pillars: research and development, production, and marketing of pharmaceuticals and health products. Research and development is the core of IX Biopharma's business model. The company continuously invests in developing new and innovative compounds and therapies for the treatment of neuropsychiatric disorders such as schizophrenia, depression, anxiety disorders, and ADHD. IX Biopharma collaborates closely with leading research institutions and experts in this field. The second pillar of IX Biopharma's business model is the production of pharmaceuticals and health products. The company relies on modern production technologies and strict quality standards to ensure that its products meet the highest requirements. Currently, IX Biopharma offers a wide range of products, including prescription and over-the-counter drugs, dietary supplements, and herbal remedies. The third pillar of IX Biopharma's business model is the marketing of its products. The company employs a comprehensive multi-channel strategy that allows the distribution of its products through various channels, including pharmacies, doctors, online shops, and other retailers. The company uses a targeted and audience-specific marketing strategy to raise awareness about its products and increase sales. One of IX Biopharma's key products is Wafermine, a medication used for the treatment of schizophrenia and other neuropsychiatric disorders. Wafermine is a novel drug developed based on Ibuprofen and offers a promising approach to treating these conditions due to its unique mechanism of action. The company is currently working on developing additional products such as dietary supplements and herbal remedies to expand its product portfolio and strengthen its position in the market. Overall, IX Biopharma's business model aims to gain a competitive advantage and achieve long-term growth by developing and marketing innovative compounds and therapies for neuropsychiatric disorders. The company relies on scientific excellence, cutting-edge technologies, and a targeted marketing strategy to achieve its goals.

IX Biopharma разпределя дивидента от 0 SGD на плащания годишно.

Дивидентата за IX Biopharma в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на IX Biopharma е SG1BD9000009.

Тикерът на IX Biopharma е 42C.SI.

През последните 12 месеца IX Biopharma изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква IX Biopharma да изплати дивиденда в размер на 0 SGD.

Дивидентната доходност на IX Biopharma в момента е .

IX Biopharma изплаща дивидент на тримесечие. Той се разпределя в месеците .

IX Biopharma платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 SGD. Това съответства на дивидентна доходност от 0 %.

IX Biopharma се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от IX Biopharma на 5.07.2024 г. в размер на 0 SGD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 5.07.2024 г..

Последното дивидентно плащане беше извършено на 5.07.2024 г..

През година 2023 IX Biopharma изплати 0 SGD под формата на дивиденти.

Дивидентите от IX Biopharma се изплащат в SGD.